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Abstract
Background:  Electronic monitoring (EM) is used increasingly to measure medication non-
adherence. Unbiased EM assessment requires fulfillment of assumptions. The purpose of this study
was to determine assumptions needed for internal and external validity of EM measurement. To
test internal validity, we examined if (1) EM equipment functioned correctly, (2) if all EM bottle
openings corresponded to actual drug intake, and (3) if EM did not influence a patient's normal
adherence behavior. To assess external validity, we examined if there were indications that using
EM affected the sample representativeness.
Methods: We used data from the Supporting Medication Adherence in Renal Transplantation
(SMART) study, which included 250 adult renal transplant patients whose adherence to
immunosuppressive drugs was measured during 3 months with the Medication Event Monitoring
System (MEMS). Internal validity was determined by assessing the prevalence of nonfunctioning EM
systems, the prevalence of patient-reported discrepancies between cap openings and actual intakes
(using contemporaneous notes and interview at the end of the study), and by exploring whether
adherence was initially uncharacteristically high and decreased over time (an indication of a possible
EM intervention effect). Sample representativeness was examined by screening for differences
between participants and non-participants or drop outs on non-adherence.
Results: Our analysis revealed that some assumptions were not fulfilled: 1) one cap malfunctioned
(0.4%), 2) self-reported mismatches between bottle openings and actual drug intake occurred in
62% of the patients (n = 155), and 3) adherence decreased over the first 5 weeks of the monitoring,
indicating that EM had a waning intervention effect.
Conclusion: The validity assumptions presented in this article should be checked in future studies
using EM as a measure of medication non-adherence.
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Background
The introduction of electronic monitoring (EM) for
assessing medication non-adherence has enabled
researchers and clinicians to gather detailed data about
medication-taking behavior. EM systems use pill bottles
containing a small electronic processor that records the
date and time of each cap opening, resulting in a more
detailed non-adherence measurement. Compared to
other methods (e.g., assay, self-report, collateral report,
prescription refills), EM captures more of the dynamics of
medication-taking behavior [1]. Although EM has for this
reason been used as gold-standard method for assessing
medication adherence [2,3], empirical evidence and clin-
ical experience suggest that several factors can jeopardize
the internal and external validity of EM studies [4]. Unbi-
ased EM measurement depends on the fulfillment of at
least four assumptions. The first 3 of these assumptions
ensure internal validity: 1) correct functioning of the EM
equipment, 2) correspondence between EM-bottle open-
ings and actual intake of the prescribed dose, 3) and
absence of an EM-associated influence on a patient's nor-
mal adherence behavior. The fourth assumption ensures
external validity: use of EM does not bias the representa-
tiveness of the sample. This article discusses processes that
might lead to a violation of these assumptions and
describes how the assumptions were empirically tested.
Figure 1 outlines the possible effects of these assumption-
violating processes on adherence measurement (i.e.,
whether they lead to overestimation or underestimation
of non-adherence).
Assumptions underlying valid electronic medication 
adherence monitoring: Internal validity
Assumption 1
The first assumption ensuring unbiased assessment of
medication non-adherence requires that electronic moni-
toring equipment function properly (Figure 1). Quality
tests of the widely used Medication Event Monitoring Sys-
tem (MEMS®-6, Aardex Ltd.) revealed that the system per-
formed well under normal or extreme laboratory
conditions (i.e., if exposed to heat, cold, shocks, or water).
A failure rate of below 0.5% is reported [5]. Reports of
how MEMS performs in the field show a similar pattern.
A two-month assessment of eleven purposively sampled
MEMS-IV bottles used in a one-year study of HIV patients
(in which a number of bottles were suspected of being
damaged) showed that EM failed to register only 2.5% of
the generated events [6]. Non-functional MEMS-V caps
are also noted in an EM study in kidney transplant
patients [7]. The exact number of non-functional caps,
however, could not be inferred from these research
reports.
Assumption 2
The second assumption ensuring unbiased assessment of
medication non-adherence requires that each time the
patient unscrews the EM-bottle cap he/she also ingests the
prescribed dose immediately. Validity of EM data can be
affected because of discrepancies in pill removal and
actual ingestion time (Figure 1). If patients correctly ingest
the immunosuppressive medication either from a source
other than the EM bottle or from a supply of pills previ-
ously removed from the EM bottle [6,8], for example
because the EM bottle is unpractical or embarrassing for
privacy reasons [9,10], non-adherence will be overesti-
Overview of possible violations of the assumptions underlying internal and external validity of EM: effects on the non-adher- ence estimate Figure 1
Overview of possible violations of the assumptions underlying internal and external validity of EM: effects on the non-adher-
ence estimate.
   Internal  validity  External  validity
Assumption 1. EM equipment 
functions correctly 
2. All EM-bottle openings correspond to actual intake of the 
prescribed dose 
3. EM does not influence 
typical adherence 
behavior 
4. Use of EM does not 
bias the sample 
representativeness 
                   
Processes 
violating this 
assumption?
Non-functioning EM 
system technology 
 Interference 
with other 
adherence 
strategies 
(e.g., pill organizer)
Intervention 
effect of 
starting EM 
Refusal to 
participate 
     3.a
Drop
-out
  
Loss of 
data 
Registration 
failures
Too many       
1.b
Opening of the EM 
bottle without 
ingestion or with 
ingestion occurring at 
a later time 
2.b     
       2.c 
Ingestion of a 
dose larger or 
smaller than 
dose prescribed
   
    
2.d 
    
  
 3.b 
  
3.c 
registrations  
    
1.a 
Correct intake of prescribed 
drugs from a non-EM 
source (e.g., after having 
removed the prescribed 
dose from the EM bottle) 
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3.d      
Effect of the 
violation 
                 Overestimation of  
                          non-adherence 
     Underestimation of  
 non-adherence 
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mated. This also includes patients who "trigger" their bot-
tles while taking medications from another source, but
who remove and replace the cap too quickly for an open-
ing to be recorded (see Figure 1, arrow 2.a). Under- or
overestimation may also occur when patients open the
EM bottle but do not remove any pills, as has been
reported in 26% of patients on HIV medication (e.g., to
demonstrates the EM system to friends; Figure 1, arrow
2.b/c) [11,6]. Likewise, ingesting doses that are larger or
smaller than those prescribed will result in underestima-
tion of non-adherence (Figure 1, arrow 2d).
Under- or overestimation of non-adherence can, to some
extent, be prevented by asking patients to report discrep-
ancies between cap openings and pill intakes and using
these reports to adjust the raw EM data, or censor periods
where the EM bottle was not used properly [8]. Several
studies have implemented this method by giving patients
a form on which to write down occurred discrepancies
[9,12]. Drawbacks of this method is that it introduces bias
itself [8]. Patients who are non-adherent to the medica-
tion therapy are also likely to keep poor records of dis-
crepancies [13]. Also, asking patients to keep notes might
induce self-monitoring and thus become an adherence-
enhancing intervention.
Assumption 3
The third assumption underlying valid EM measurement
requires the absence of an EM-induced effect on a
patient's normal or typical adherence behavior (Figure 1).
Two pathways are important in this regard. Firstly, EM
may influence normal intake behavior because patients
cannot use medication aids like pill organizers as usual
and, at the same time, be electronically monitored [4].
Secondly, the awareness of being monitored may change
the patient's typical adherence habits [14]. Using a pill
organizer can increase the burden of a patient participat-
ing in an EM study, and lead to a lower participation to
EM-studies among the pill-organizer users [4], or to stop-
ping to use the pill organizer when continuing to be part
of the study [15] (Figure 1, arrow 3.a). The problems
related to combining an EM bottle and a pill organizer are
expected to result in overestimating non-adherence
(arrow 3.b). Support for the hypothesis that the awareness
of being monitored may change a patient's typical medi-
cation-taking habits comes from patient reports indicat-
ing that being electronically monitored influences normal
intake behavior. In most cases, patients reported an
increased adherence, seldom a decreased one
[16,9,12,17,18,4] (Figure 1, arrows 3.d & 3.c). Support
from sources other than these patient reports is scarce.
These sources are summarized in Table 1. Five interven-
tion studies examined whether administering EM
[14,16,19] or disclosing the monitoring purpose of EM
[13,20] changed a patient's typical adherence behavior
and one observational study examined whether non-
adherence increased over time after having started EM
[21]. The results from these studies were inconclusive. The
studies of Elixhauser et al. (1990) and Bertholet et al.
(2000) confirmed that starting EM alters adherence
behavior, while the other studies could not find any dif-
ference. The latter finding most probably reflected the
existence of methodological weaknesses, rather than the
absence of an EM-related intervention effect. A study over-
coming most of the methodological flaws of currently
published studies should include a large enough sample,
evaluate a possible intervention effect at different time
points, use statistical tests properly, and adopt a non-
adherence measurement method independent of a
patient's awareness (thus not self-report).
Assumption underlying valid electronic medication 
adherence monitoring: External validity
The fourth assumption refers to issues that might threaten
the representativeness of the sample of an EM study.
Examples include a large proportion of eligible subjects
refusing to participate and a large proportion of patients
dropping out of a study. The term dropout refers to
patients who leave the study, who do not send their EM
caps back to the research team, or who do not adhere to
the instructions regarding EM use (resulting in unreliable
EM data). Limited evidence exists concerning the external
validity of EM studies in the literature. In one study, a
smaller number of pill-organizer users decided to partici-
pate in EM than did non-users; the authors attributed this
disparity to the burden of combining EM with pill organ-
izers [4]. Another study found that especially patients
non-adherent to the medication have difficulties also to
be adherent to the guidelines of the assessment [13].
Purpose of the study
Because no study to date has tested the four above men-
tioned assumptions, the aim of the present study was to
examine whether these assumptions were fulfilled when
using EM in a sample of kidney transplant patients. More
specifically, we aimed 1) to examine the accurate func-
tioning of EM technology, 2) to check the correspondence
of recorded EM-bottle openings with the actual intake of
the prescribed dose, 3) to test whether EM influenced the
typical adherence behavior of patients, and (4) to exam-
ine whether using EM biased the representativeness of the
sample.
Methods
Design, sample, and setting
Data for this prospective cohort study came from the Sup-
porting Medication Adherence in Renal Transplantation
(SMART) study, which focused on prevalence and deter-
minants of non-adherence [22]. Patients were eligible if
they had received their kidney transplant at least one yearBMC Medical Research Methodology 2008, 8:5 http://www.biomedcentral.com/1471-2288/8/5
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prior to enrollment, and if they were self-administering
immunosuppressive medication, more than 18 years of
age, German or French speaking, and literate. Patients
were excluded if they were not mentally able to respond
adequately to the researcher's questions or to complete
the questionnaires. The convenience sample consisted of
patients followed up at two outpatient transplant clinics
in Switzerland. Swiss health insurance, which is compul-
sory, largely covers costs for immunosuppressive medica-
tions. Patients are responsible for paying out-of-pocket
expenses amounting to about 10% of costs for prescribed
drugs.
Variables and measurement
We used the Medication Event Monitoring System
(MEMS-5 TrackCap, Aardex Ltd., Zug, Switzerland) to
measure non-adherence to immunosuppressive medica-
tions. The monitoring lasted three months and focused on
one immunosuppressive drug per patient, preferably one
taken twice daily (cyclosporine, tacrolimus, mycopheno-
Table 1: Published studies testing a possible intervention effect of electronic-medication monitoring on typical medication-taking 
behavior
Author & 
publication 
year
Study design Description of 
the sample
n EM Description of 
the 
intervention
Outcome 
variable: 
medication 
adherence or 
clinical outcome
Result
Wagner et al. 
2002
Randomized 
controlled trial
A community 
convenience 
sample of adult 
HIV-positive 
patients on 
HAART
117 MEMS Experimental 
group received 
EM; control group 
did not
Adherence measured 
with self-report 4 
weeks after study 
start (% of 
prescribed pills 
taken)
Less adherence in 
the EM group 
(91%) than in the 
control group 
(94%; p=.73)
Pre-post 
intervention 
study
A community 
convenience 
sample of adult 
HIV-positive 
patients on 
HAART monitored 
with EM
60 MEMS EM started after 
baseline blood 
pressure 
measurement
Adherence measured 
with self-report at 
baseline and after 4 
weeks
Less adherence 
after introducing 
EM (91%) 
compared to 
baseline (93%; 
p=.16)
Bertholet et al. 
2000
Pre-post 
intervention 
study
A convenience 
sample of primary 
care/hypertensive 
clinic patients with 
therapy-resistant 
hypertension
69 MEMS EM started after 
baseline blood 
pressure 
measurement
Clinical outcome: 
blood pressure 
evaluation after 1 – 2 
months
Blood pressure 
was lower after EM 
(14/9 cm Hg) 
compared to 
baseline (16/10 cm 
Hg; p < .001)
Matsui et al. 
1994
Pre-post 
intervention 
study
A convenience 
sample of young β-
thalassemia 
outpatients on a 
new iron chelator
10 MEMS The purpose of 
EM was disclosed 
to patients after ± 
11 months
Adherence measured 
by EM using the 
taking adherence 
parameter ± 18 
months after 
disclosure
Greater adherence 
after disclosure 
(84%) compared to 
before (77%; 
p=.49)
Yeung et al. 
1994
Quasi-
experimental 
study
Non-equivalent 
study: two 
convenience 
samples of asthma 
patients on inhaling 
therapy
21 MDI Intervention 
group given 
disclosure; 
control group not 
given disclosure
Adherence measured 
by EM using the 
taking adherence 
parameter after 2 – 3 
weeks from the 
study start
Greater adherence 
in the disclosed 
group (81%) than 
in the undisclosed 
group (71%; p=.53)
Elixhauser et al. 
1990
Randomized 
controlled trial
A convenience 
sample of 
psychiatric 
outpatients treated 
with lithium
90 Blister package Experimental 
group received 
EM; control group 
did not
Adherence measured 
by self-reported, 
assay, % of expected 
prescription refills 
(after 2 – 4 months 
of study start)
Fewer expected 
prescription refills 
in the EM group 
(18%) than in the 
control group 
(31%; p < .01)
Cramer et al. 
1990
Observational 
study
An unspecified 
sample of patients
24 MEMS All patients 
received EM
Adherence measured 
by EM using the 
taking adherence 
parameter during the 
first and after a mean 
of 7 months from the 
start of the study
No difference 
before and after 
(79% vs. 79%).BMC Medical Research Methodology 2008, 8:5 http://www.biomedcentral.com/1471-2288/8/5
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late mofetil). To capture the two dosing times of patients
taking a combination of azathioprine and prednisone,
both of which are typically prescribed once daily, we
monitored the usage of both drugs. EM bottles were pre-
pared in the hospital pharmacy and sent to the patients.
When a bottle was empty, the patient received a new one
to which the EM cap could be attached. All patients
received information about the monitoring of their med-
ication-taking behavior, as requested by the ethical com-
mittee.
Adherence to the EM instructions
All participants received verbal and written instructions
on how to use the EM system. Instructions stressed the
need to match EM-bottle openings with actual drug
intakes, and requested patients to describe any deviations
from this guideline on the form accompanying the EM
bottle. Examples of such guideline violations include
inadvertently opening the EM bottle when no medication
was required, stopping EM bottle use for a period, remov-
ing pills prematurely, triggering the cap while not remov-
ing medication from the bottle opening (e.g. taking
medication from another source, cutting a hole in the bot-
tom of the EM bottle and removing medication from
there, ...). Upon completion of the EM measurements, we
integrated the resulting patient notes into the uploaded
EM data.
At the end of the 3-month EM period, we also used a struc-
tured interview to assess perceived adherence to the EM
instructions. The first goal of this interview was to detect
defined periods of non-adherence to the EM instructions
and to censor these data from the analysis (e.g., when a
patient failed to use the EM device during the holidays for
14 days). The second goal of the interview was to assess
the quality of the remaining data by scoring them accord-
ing to five quality standards: 1) strict adherence to the EM
guidelines (5 points); 2) self-report indicated that the EM
system was not used exactly as instructed, but complete
notes were available (4 points); 3) self-report indicated
that the EM system was not used exactly as instructed, but
incomplete notes were available (3 points); 4) self-report
indicated that the EM system was not used exactly as
instructed, but no notes were available (2 points); and 5)
self-report indicated that neither the EM bottle nor the
form was used as instructed (1 point) (Figure 2). This
quality assessment tool was developed with consideration
for patients' reports (recorded in field notes and later cat-
egorized) of how well they had been able to the EM use
instructions. Data were considered to be of sufficient qual-
ity for analysis when the patient received a score of 3
points or higher. At the end of the monitoring period,
patients were also asked whether they perceived that using
EM influenced their normal medication-intake behavior,
and whether this influence changed their typical adher-
ence to the immunosuppressives positively or negatively.
Dropped EM caps
We asked the patients to report on their form whether
they had dropped their EM caps to determine whether
dropping the caps damaged the caps' recording capacity.
When the patients indicated that a drop had occurred, we
checked whether the recording system still functioned
properly by scanning the uploaded EM data visually for
extra recordings or for altered registration patterns (e.g. no
further registered openings).
Operational definition of EM-measured adherence
Electronically measured non-adherence was evaluated for
each prescribed intake moment. Two binary variables rep-
resented the taking and timing dimensions of the patients'
non-adherence. The first variable indicated whether a
patient omitted a dose (taking dimension). The second
variable indicated whether on each expected intake
moment, the monitored inter-dose interval deviated by
more than 25% from the prescribed interval (timing
dimension).
Other variables included in this study
To compare the characteristics of patients included in the
EM study with those that refused to participate or dropped
out, we measured non-adherence to the immunosuppres-
Algorithm estimating a patient's non-adherence to the EM guidelines Figure 2
Algorithm estimating a patient's non-adherence to the EM guidelines.
Self-reported EM bottle use  Self-reported  non-adherence 
to the EM guidelines
   Data quality
          
Yes      5  Adherence to the EM guidelines 
   •  Complete  notes  4 
  Sometimes   • Some notes  3 
Minor non-adherence to the EM guidelines 
 Data included in the analyses 
EM  
system 
always  
used as  No    • No notes  2 
Instructed?   Never   1 
Major non-adherence to the EM guidelines 
 Data excluded from the analyses BMC Medical Research Methodology 2008, 8:5 http://www.biomedcentral.com/1471-2288/8/5
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sive therapy using self-report, collateral report, and blood
assay. In the self-report, patients used a 7-point scale to
score the frequency of non-adherence during the four
weeks just prior to the inclusion interview – the scale
ranged from never (0 points) to every day (6 points). This
ordinal non-adherence variable was assessed during the
inclusion interview. In the collateral report, nurses and phy-
sicians involved in the follow-up care of the transplant
patients scored non-adherence using a 3-point scale –
good adherence (1 point), fair adherence (2 points), bad
adherence (3 points). We used the mean scores of the
health-care workers who evaluated and scored patients.
With regard to the blood assay, we considered one measure-
ment moment, namely the patient's drug trough levels at
inclusion in the study (i.e., of cyclosporine, mycopheno-
late mofetil, tacrolimus, or sirolimus before the morning
dose was ingested).
Data collection
This study was conducted in compliance with the regula-
tions of the Ethical board of the Canton Basel-Stadt gov-
erning the protection of human subjects in research
(Vereinbarung Ethikkommission beider Basel GS
300.400). The study was reviewed and approved by the
ethical committee of the Canton Basel-Stadt (55/00), and
the ethical committee of the Swiss Academy of Medical
Sciences (PV124/00-SNF) and patients signed informed
consents. We collected data from June 2001 to January
2004. Four research staff members recruited the patients,
collected demographic and self-reported non-adherence
data, and instructed the patients on how to use the EM
system. After three months of electronic monitoring, par-
ticipants received a letter to remind them to either bring
back the EM device to the outpatient clinic or to send it
back to the researchers (in a pre-stamped and pre-
addressed envelope). Upon return of the device, we tele-
phoned the patients and carried out a structured interview
to assess their adherence to the EM guidelines (see Figure
2). During the interview, we also sought to determine how
EM may have influenced the patients' typical adherence
behavior. We used Powerview®  hard- and software to
upload and adjust the EM data according to the patients'
notes.
Data analysis
We calculated the prevalence of malfunctioning EM sys-
tems (assumption 1), the prevalence of reported cap
recording mismatches and non-adherence to the EM sys-
tem (assumption 2), and the proportion of pill organizer
users not participating (assumption 4). We also compared
tabulated mean values of non-EM measured adherence
between participants and non-participants/dropouts and
tested for differences using the Wilcoxon-Mann-Whitney
test (assumption 4).
Regarding assumption 3, we modeled the probability of
non-adherence as a function of a patient's exposure time
to the EM system by performing two multiple random-
intercepts logistic regression analysis, one modeling dose
omissions and one timing non-adherence. The random-
intercepts models, which we fitted using the 'nlmixed'
procedure in SAS® version 9.1, accounted for the repeated
measurement structure of the data. These multiple models
controlled for the variables "bottle volume" (1055 cc, 325
cc, 120 cc), "the researcher who did the inclusion inter-
view", and "the self-reported perceived EM-intervention
effect" (positive or not). To get a more detailed insight
into a possible non-linear course of non-adherence over
time, we also fit a generalized additive model including a
spline-smoothed function of exposure time (SAS 'gam'
procedure) [23]. The method allowed graphical explora-
tion of nonlinearities by leaving the relationship between
non-adherence and exposure time unspecified.
Results
Four hundred thirteen adult renal transplant recipients
visiting the outpatient clinic for their yearly check-up were
asked to participate in the SMART study (Figure 3). Three
hundred fifty-six accepted (86%) and 57 (14%) refused to
participate in our study. Of the 57 patients, 28 granted us
permission to obtain their demographic and clinical data
from their medical files. Of the 356 participating patients,
291 (82%) agreed to be monitored electronically. The
remaining 65 (18%) patients did not want to be moni-
tored electronically but wanted to participate by complet-
ing the self-report questionnaires. Of the 291 patients
who agreed to be monitored with EM, 3 (1%) never
started, 3 (1%) did not return their EM caps, and one died
(< 1%). Thirty-four (12%) patients were excluded from
the analyses because, according to the data quality assess-
ment outlined in the methods section and illustrated in
figure 2, they failed to adhere to the EM guidelines (scores
4 and 5). The final sample consisted of 250 patients, with
an average age of 54 years (sd = 13). The majority of sub-
jects were Swiss citizens (n = 209; 84%) and male (n =
142; 57%). Immunosuppressive therapies consisted of
cyclosporine and mycophenolate mofetil (n = 71; 28%),
cyclosporine (n = 38; 15%), cyclosporine and azathio-
prine (n = 37; 15%), or other combinations (n = 104;
42%). Further details regarding the sample characteristics
can be found in Table 2.
Assumption 1
Sixty-one (24%) patients reported that they had dropped
their EM caps. None of these caps registered the drop as an
event, nor did the data afterwards reflect any visually
detectable signs of damage to the recording system. One
patient (0.4%) who never dropped his cap claimed to
have better adherence than suggested by his EM data. We
manually checked his cap, which revealed that it failed toBMC Medical Research Methodology 2008, 8:5 http://www.biomedcentral.com/1471-2288/8/5
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register openings. The manual check was done by one of
the investigators, who unscrewed the cap from the bottle
for one week and downloaded the registrations onto the
computer. No openings were registered. This cap seemed
to have gradually lost its registration capacity during the 3-
month monitoring period, because all expected openings
within the first two weeks of the measurement period
were recorded, after which the event recordings declined.
Although the gradual decline of cap function suggested a
battery problem, a battery check did not reveal an
exhausted battery.
Assumption 2
Of the 249 patients with reliable EM data (= 250 minus
the failed cap), 155 (62%) reported discrepancies on their
form between recorded openings and actual medication
intakes, which required 1084 adjustments to the 44761
events of the final data base (2.4 adjustments, on average,
per person). Twenty-eight percent of the adjustments
involved early decants of pills that were ingested later. The
most frequently mentioned reasons patients gave for the
discrepancies were going out, being on a trip, and having
a meeting. Other reasons for correspondence failures were
taking medication from another supply, phantom open-
ings to demonstrate the EM bottle to visitors, and opening
the wrong bottle. Twenty-three patients (9.2%) had
defined periods of non-adherence to the guidelines of cor-
rect EM use according to the used data quality algorithm
(figure 2). For these patients, an average of 13.6 days was
censored from the total monitoring period. Censoring
these days increased the average percentage of correctly
dosed days from 92.9% to 96.3%.
Assumption 3
The random-intercepts logistic regression analysis con-
firmed an increase in both taking and timing non-adher-
ence over time (Table 3). The odds on non-adherence
increased over one month by about 30% for taking (OR:
1.31; 95%CI: 1.17–1.46) and 25% for timing adherence
(OR: 1.26; 95% CI: 1.17–1.35). In addition, the nonlinear
regression lines showed that the increase in both dimen-
sions mainly occurred during the first 5 weeks of monitor-
Table 2: Characteristics of the sample (n = 250)
Variable Categories Value
Age Mean= 54 (sd = 13)
Gender Male 142 (56.8%)
Living alone No 194 (77.6%)
Employed Yes 130 (52.0%)
Education until age 11/12 years 33 (13.2%)
until age 12/13–14/15 years 118 (47.2%)
until age 15/16–18/19 years 26 (10.4%)
advanced (college) 73 (29.2%)
Nationality Swiss 209 (83.6%)
Immunosuppression Cyclosporine & mycophenolate mofetil 71 (28.4%)
Cyclosporine 38 (15.2%)
Cyclosporine & azathioprine 37 (14.8%)
Azathioprine & prednisone 18 (7.2%)
Azathioprine & tacrolimus 14 (5.6%)
Other combinations 72 (28.8%)
Monitored immunosuppressives Mycophenolate mofetil 103 (41.2%)
Cyclosporine 89 (35.6%)
Azathioprine/prednisone 19 (7.6%)
Tacrolimus 37 (14.8%)
Sirolimus 2 (0.8%)
Self-reported EM influence on typical adherence No influence 188 (76.1%)
Positive influence 53 (21.5%)
Negative influence 6 (2.4%)
Patient-sample profile Figure 3
Patient-sample profile.
413 patients invited to participate in study 
  
57 (13.8%) 
refusals 
    356 (86.2%) 
acceptances 
  
28 (49.1%) 
background data 
extraction granted 
65 (18.3%) 
without EM 
  291 (81.7%)  
with EM 
  284 with data       6 without data 
- 3 never started  
- 3 did not return cap 
- 1 died 
  34 (12.3%)  
displayed major non-
adherence to the EM 
guidelines 
 250 (87.7%)  
adhered to the EM 
guidelines 
   193  (77.5%) 
adhered to 
the EM guidelines 
(of which 1 cap deficit) 
46 (18.5%) 
displayed minor non-adherence 
to the EM guidelines BMC Medical Research Methodology 2008, 8:5 http://www.biomedcentral.com/1471-2288/8/5
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ing (Figure 4). After day 35, the taking dimension of non-
adherence stabilized. The average percentage of correctly
dosed days was 96.7% when including the entire 3-month
measurement period, but slightly decreased to 96.3%
when the first 35 days were excluded. The timing dimen-
sion of non-adherence stabilized after about day 50. The
average percentage of correctly timed intakes was 91.8%
when including all data points, and slightly decreased to
91.4% when only considering the stable phase between
day 50 and 75. A post hoc analysis identifying potential
interactions between exposure to EM and perception of
the EM-intervention effect, showed a stronger EM-inter-
vention effect in patients acknowledging an intervention
effect than in patients stating that they experienced no
intervention effect (p = 0.003).
Assumption 4
A comparison of pill organizer use in participants vs. non-
participants in the EM part of our study showed that pill-
box use was more common among non-participants
(38.5%) than among participants (25.1%: p = 0.03).
Table 4 compares non-EM adherence measurements of
participants and non-participants/dropouts (i.e., self-
report, collateral report and blood assay). We did not find
any statistically significant evidence that dropouts or non-
participants had a lower adherence to the immunosup-
pressive therapy than participants.
Discussion
This study examined four assumptions underlying the
valid electronic measurement of medication non-adher-
ence, which, if violated, might threaten the external and/
or internal validity of EM studies.
Assumption 1
We identified one EM device that had stopped recording
cap openings during the study (0.4%). The failure rate is
similar to that reported on the Aardex website (< 0.5%),
and confirms literature reports that EM devices used in
studies can be damaged [6,7]. Although our study evalu-
ates the MEMS-5 monitors, and not the newer MEMS-6
monitors Aardex refers to, MEMS-6 differs from MEMS-5
mainly in its data upload technology. MEMS-6 is compa-
rable to its predecessor regarding most other features [24].
The result of our study can thus be considered representa-
tive for the system currently on the market. The existence
of a non-registering cap shows that non-adherence overes-
timation is possible for a small number of patients who
Table 3: Estimates and inferences from the multiple logistic random-intercept models predicting the chance of non-adherence
Outcome variable Parameter Estimate Standard error Odds ratio (95% 
confidence interval)
DF t value p value
Omitted intakes Random-intercepts variance 2.845 0.445 241 6.39 < .0001
Intercept -5.900 0.470 241 -12.54 < .0001
Exposure to EM (per month) 0.270 0.055 1.31 (1.17–1.46) 241 4.91 < .0001
Bottle size (per 100 ml) 0.014 0.040 1.01 (0.94–1.10) 241 0.93 0.35
Influence perception 0.277 0.328 1.32 (0.69–2.52) 241 0.84 0.39
Interviewer 1 vs. interviewer 4 0.461 0.356 1.59 (0.79–3.19) 241 1.29 0.19
Interviewer 2 vs. interviewer 4 0.011 0.365 1.01 (0.50–2.07) 241 0.03 0.97
Interviewer 3 vs. interviewer 4 0.022 0.438 1.02 (0.43–2.42) 241 0.05 0.95
Intake variability Random-intercepts variance 3.486 0.422 241 8.26 < .0001
Intercept -3.033 0.414 241 -7.31 < .0001
Exposure to EM (per month) 0.227 0.036 1.26 (1.17–1.35) 241 6.67 < .0001
Bottle size (per 100 ml) -0.106 0.037 0.90 (0.84–0.97) 241 -2.08 0.04
Influence perception 0.011 0.314 1.01 (0.54–1.88) 241 0.04 0.97
Interviewer 1 vs. interviewer 4 0.704 0.340 2.02 (1.04–3.95) 241 2.07 0.04
Interviewer 2 vs. interviewer 4 0.008 0.344 1.01 (0.51–1.99) 241 0.02 0.98
Interviewer 3 vs. interviewer 4 0.148 0.422 1.16 (0.50–2.67) 241 0.35 0.73
Observed course of non-adherence over time Figure 4
Observed course of non-adherence over time.BMC Medical Research Methodology 2008, 8:5 http://www.biomedcentral.com/1471-2288/8/5
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have damaged caps that remain undetected. A systematic
check of the recording system before and after a monitor-
ing period is advisable.
Assumption 2
The present study revealed that EM registrations in our
sample often did not correspond to the actual ingestion of
the monitored medication. Our results are similar to a
study of HIV patients, where 36% failed to use the EM bot-
tles continuously during a one-year monitoring period,
38% used their EM bottles only on occasion, and 3%
always removed more than one dose per EM-bottle open-
ing [6]. As already suggested previously in a study using
fabricated data [8], we showed that choosing to censor
time periods clearly affects the obtained prevalence of
non-adherence. Our uncensored data showed a 3.4%
higher non-adherence than the censored data, which
could be considered as an overestimation of non-adher-
ence. Due to technical reasons, we were not able to also
examine the effect of data adjustment (based on the forms
accompanying the EM bottle), but it may be safely
assumed that the non-adherence overestimation would
have been even larger if we also omitted the patient-
reported discrepancies. Nevertheless, a study supported
by Aardex showed that uncorrected EM monitoring ena-
bles accurate estimation of patient's drug exposure. How
accurately patients adhered to the EM instructions is not
known [25]. The fact that in our study, patients seem to
not always adhere fully to the guidelines for MEMS use is
not necessarily a drawback of the idea of EM itself. How-
ever, one can conceive of a system that is easier to use and
invokes less resistance [6]. A more practical, easy-to-use
system may increase EM use outside of the home, thereby
increasing the correspondence between event registration
and pill ingestion. Recent efforts are being made in this
regard in that several companies have started to market
EM-blister packs that can be easily carried along: Bang &
Olufsen's IDAS®, IMC's Med-ic®, and MeadWestvaco's
Cerepak®.
We are aware that our attempts to estimate the adherence
of patients to the EM instructions rely on patient self-
reports, which is not a highly sensitive measurement
method. However, in the case of the patient reports we
used to supplement missing or correct phantom registra-
tions, recall bias could not have been a large problem
because the notes were recorded at the time of each event
or not long thereafter. The interview at the end of the
measurement period asked for a general impression of the
use of the bottle and the notes form, not for detailed
adherence information. Even if less reliable than other
sources, this kind of patient report may result in a more
accurate measurement than simply not correcting the data
with information given by the patient. When a patient for
instance assures that during a holiday period the monitor
was left at home while medication was taken from
another source, it would be less accurate to discard this
information and rely blindly on the monitor's records
than to use this information to interpret the missing data
in the EM records. Future studies should be clear about
how they dealt with issues of non-adherence to the EM
system. Few studies to date report on these issues. Because
the decisions made by the investigators to clean their data
have an effect on the obtained results, and may even intro-
duce other forms of bias, more openness is needed in
future research. Investigators may be helped in this regard
by a recently published checklist that aims at conceptually
clarifying EM data management decisions [8].
Assumption 3
Testing the third assumption revealed that EM might have
influenced adherence behavior. The prevalence of non-
adherence was very low in the beginning of the monitor-
ing period. A subsequent increase of non-adherence prob-
ably reflects the waning of the adherence-enhancing effect
of introducing EM to patients' daily lives, although our
sensitivity analysis showed that omitting the first month
did not lead to a large increase of the prevalence of non-
adherence, implying that the observed intervention effect
had only minor clinical relevance. The absence of a con-
trol group prevents drawing firm conclusions, but the fact
that our research group found the same pattern in HIV
patients strengthens this hypothesis [26]. Traditional
analysis approaches, using period prevalence parameters
like "the percentage of prescribed medications that are
taken", are limited with regard to analysis of detailed
time-dependent evolutions. Moreover, their often J-
shaped distributions force researchers to rely on simple
nonparametric tests [27]. Although we only found mini-
mal differences in prevalences including the intervention
period compared to prevalences excluding it, bias may
increase when the proportion of the intervention period is
high compared to the whole monitoring period, which
may be the case with studies lasting only a month. Studies
assessing patients' normal level of adherence should
therefore examine presence and duration of an interven-
tion effect using longitudinal analysis techniques [28]. It
has to be noted that all ethically permissible adherence
assessment methods, electronic or otherwise, require the
consent of the subject, and therefore influence the
observed behavior. It is well-documented, for example,
that blood assays lead to white-coat adherence [29], and
that self-report also influences the self-reportet adherence
behavior [30]. The fact that our researchers were not
blinded may also have influenced the occurrence and
strength of the intervention effect. The found significant
difference in patient's timing adherence between two of
the researchers (Table 3), may be an indication of this
influence. Differences could occur if patient recruitmentBMC Medical Research Methodology 2008, 8:5 http://www.biomedcentral.com/1471-2288/8/5
Page 10 of 11
(page number not for citation purposes)
was accompanied by stressing on the importance of being
adherent to the immunosuppressive regimen.
Assumption 4
We found little evidence of compromised external validity
in this sample of renal transplant patients. Our study con-
firmed previous research showing less agreement to par-
ticipate in EM assessment where patients said they used a
pill organizer, suggesting selection bias [4]. This may be
because subjects perceive an extra burden in managing an
organizer and a MEMS bottle at the same time. Our study
failed to confirm the hypothesis that patients who did not
adhere to EM guidelines, display higher medication non-
adherence than patients who did adhere to the guidelines
[13]. This does not necessarily mean that there was no dif-
ference: measurement error coming from small sample
sizes, low sensitivity of non-EM non-adherence assess-
ment [1], and low sensitivity of our EM-data quality
assessment, may have blurred existing differences. This
assumption should be further investigated.
Conclusion
This article on the validity of electronic monitoring of
non-adherence to medication shows the challenge of dis-
entangling non-adherence measurement from processes
that bias the EM measurement. We hope that our study
helps to increase awareness among adherence researchers
of the complexity of electronically monitoring medication
taking, and that it acts as an impetus for the improvement
of EM use. We offered a set of requirements essential to
enhance methodological quality of future EM studies.
Specifically, EM studies should 1) perform a systematic
functionality control of the EM system before and after
use; 2) assess adherence to the EM guidelines; 3) examine
intervention effects; and 4) examine sample representa-
tiveness. Meeting these methodological standards plus
being transparent in the reporting on the exact operation-
alization of EM, may help EM to approach its gold-stand-
ard aspirations. Although the population used in this
study is not representative of all populations in which
MEMS is used, the approach we present could be used as
a model for testing assumptions in other populations.
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Table 4: Adherence comparison between participants/non-participants and participants with reliable EM data and participant 
dropouts
Variable Subgroups
Non-participants Non-participants Participants
median iqr b n median iqr n
Self-report a 0.0 0.0 65 0.0 0.0 284
Collateral report a 1.0 0.1 35 1.0 0.3 164
Assay: cyclosporine (mmol/l) 112.5 50.0 50 105.0 56.0 191
Assay: tacrolimus (mmol/l) 7.6 3.2 21 7.2 3.9 44
Assay: sirolimus (mmol/l) 14.3 4.2 5 8.8 9.5 15
Assay: mycophenolate mofetil (mmol/l) 3.3 1.8 41 2.6 1.9 122
Dropouts Non-adherers to the EM guidelines Adherers to the EM-guidelines
median iqr n median iqr n
Self-report 0.0 0.0 36 0.0 0.0 244
Collateral report 1.0 0.7 35 1.0 0.3 224
Assay: cyclosporine (mmol/l) 108.0 43.0 25 104.5 58.5 164
Assay: tacrolimus (mmol/l) 6.2 6.1 5 7.2 3.7 39
Assay: mycophenolate mofetil (mmol/l) 2.7 1.8 17 2.6 1.9 101
a Definition: see section variables and measurement
b Interquartile rangeBMC Medical Research Methodology 2008, 8:5 http://www.biomedcentral.com/1471-2288/8/5
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